Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Sonrotoclax |
| Synonyms | |
| Therapy Description |
BGB-11417 selectively inhibits Bcl2, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3077). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Sonrotoclax | Beqalzi | BGB 11417|BGB11417|BGB-11417 | BCL2 inhibitor 29 | Beqalzi (sonrotoclax) selectively inhibits Bcl2, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3077). Beqalzi (sonrotoclax) is FDA-approved for use in patients with relapsed or refractory mantle cell lymphoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05952037 | Phase II | Sonrotoclax + Zanubrutinib Sonrotoclax | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | Active, not recruiting | USA | ITA | GRC | GBR | FRA | ESP | CAN | AUS | 1 |
| NCT04973605 | Phase Ib/II | Sonrotoclax Carfilzomib + Dexamethasone + Sonrotoclax Dexamethasone + Sonrotoclax Dexamethasone + Pomalidomide + Sonrotoclax Daratumumab + Dexamethasone + Sonrotoclax | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | Recruiting | USA | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |
| NCT05471843 | Phase II | Sonrotoclax | Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | Active, not recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 2 |
| NCT04277637 | Phase I | Sonrotoclax + Zanubrutinib Sonrotoclax Obinutuzumab + Sonrotoclax + Zanubrutinib | Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies | Active, not recruiting | USA | NZL | ITA | GBR | ESP | DEU | AUS | 0 |
CKB BOOST